

June 24, 2015

EQUITY RESEARCH AFTERNOON RESEARCH SUMMARY

What's Inside

Updates

TKAI	O	Tokai Pharmaceuticals, Inc.
ZMH	O	Zimmer Holdings

Today's Headlines

Zimmer Holdings (ZMH)

Steven Lichtman

[FTC Accepts Proposed Consent Order on ZMH/Biomet Divestitures](#)

HEALTHCARE

Akiva Felt

[Monthly Prescription Tracker](#)

Tokai Pharmaceuticals, Inc. (TKAI)

Ling Wang, CFA

[Phase III ARMOR3 Trial was Initiated on Time](#)

► **Conference Calendar**

► **Oppenheimer Sponsored Conference Calls**

► **Earnings & Conference Call Calendar**

Oppenheimer & Co. Inc. does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. See "Important Disclosures and Certifications" section at the end of this report for important disclosures, including potential conflicts of interest. See "Price Target Calculation" and "Key Risks to Price Target" sections at the end of this report, where applicable.

Snap Commentaries - Equities Updates

HEALTHCARE

[Steven Lichtman](#)

212-667-8160

Zimmer Holdings (ZMH - \$112.68)

Medical Devices

Rating	Market Cap	Price Target	Earnings Type	2014A	2015E	2016E
O	\$19,200.9M	\$124.00	EPS	6.48	6.68	7.88

[FTC Accepts Proposed Consent Order on ZMH/Biomet Divestitures](#)

Earlier today, the Federal Trade Commission (FTC) issued a press released announcing that it has accepted a proposed consent order that will settle its anti-competitive concerns from the ZMH/Biomet merger. The required divestitures detailed in the press release are consistent with ZMH's press release from May 28 which indicated that agreements have been finalized with buyers of the Zimmer US High-Flex (ZUK) unicondylar knee implant and Biomet's US Discovery Total Elbow and Cobalt Bone Cement. A standard 30-day comment period is required before a final consent order is issued, but as we've seen following previous proposed consent orders (JNJ/Synthes, others), we assume the merger closes within the next few days.

HEALTHCARE

[Akiva Felt](#)

415-399-5728

[Monthly Prescription Tracker](#)

We are launching a revamped prescription tracker utilizing data from Symphony Health, including new visualization aids on Pages 2-3. We currently track data for AMRN, ATRS, ENDP, MDCO, MNK, PTX and TEVA. As a benchmark, TRx for all primary care drugs across the industry decreased 2.0% m/m. Our next installment of the Prescription Tracker will be published on/around July 22, coinciding with Symphony Health release of monthly data.

HEALTHCARE

[Ling Wang, CFA](#)

212 667-8564

Tokai Pharmaceuticals, Inc. (TKAI - \$13.89)

Biotechnology

Rating	Market Cap	Price Target	Earnings Type	2014A	2015E	2016E
O	\$311.3M	\$38.00	EPS	(3.60)	(1.62)	(2.15)

[Phase III ARMOR3 Trial was Initiated on Time](#)

This morning, TKAI announced the initiation of the phase III ARMOR3 trial which met the management's 1H15 guidance. The components of the companion diagnostic test of the AR-V7 assay have been finalized by its collaborator Qiagen (QGEN-NASDAQ, \$24.95, Not Covered). We continue to see ARMOR 3 trial as having a favorable design (rPFS as primary endpoint/small patient size/short follow-up) and a high probability of success based on a clear MOA, promising efficacy seen in ARMOR2 trial, and Xtandi's lack of efficacy in AR-V7+ mCRPC patients.

Earnings & Conference Call Calendar

Earnings Reporting

Conference Call

Company	Ticker	Analyst	Date	Time (EST)	Tel. Number	Code	Replay	Code
Wednesday, June 24, 2015								
Bed Bath & Beyond Inc	BBBY	Nagel, CFA	24-June-15	5:00PM	+1-847-585-4405	39894286	+1-630-652-3042	39894286
Wednesday, July 01, 2015								
Acuity Brands Inc	AYI	Glynn	1-July-15	10:00AM	+1-(312) 470-7172	Acuity		

Important Disclosures and Certifications

Other companies mentioned in this report: TKAI ZMH

Important Disclosure Footnotes for Companies Mentioned in this Report that Are Covered by Oppenheimer & Co. Inc.:

Stock Prices as of June 24, 2015

Tokai Pharmaceuticals, Inc. (TKAI - NASDAQ, 13.89, OUTPERFORM)

Zimmer Holdings (ZMH - NYSE, 112.68, OUTPERFORM)

Distribution of Ratings/IB Services Oppenheimer & Co. Inc.

Rating	Count	Percent	IB Serv./Past 12 Mos.	
			Count	Percent
BUY [O/B/OP]	343	57.74	149	43.44
HOLD [N/P/SP]	244	41.08	87	35.66
SELL [UP/S/U]	7	1.18	2	28.57

Analyst Certification - The author certifies that this research report accurately states his/her personal views about the subject securities, which are reflected in the ratings as well as in the substance of this report. The author certifies that no part of his/her compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in this research report.

Other Disclosures

This report is issued and approved for distribution by Oppenheimer & Co. Inc. Oppenheimer & Co. Inc. transacts business on all principal exchanges and is a member of SIPC. This report is provided, for informational purposes only, to institutional and retail investor clients of Oppenheimer & Co. Inc. and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited. The securities mentioned in this report may not be suitable for all types of investors. This report does not take into account the investment objectives, financial situation or specific needs of any particular client of Oppenheimer & Co. Inc. Recipients should consider this report as only a single factor in making an investment decision and should not rely solely on investment recommendations contained herein, if any, as a substitution for the exercise of independent judgment of the merits and risks of investments. The analyst writing the report is not a person or company with actual, implied or apparent authority to act on behalf of any issuer mentioned in the report. Before making an investment decision with respect to any security recommended in this report, the recipient should consider whether such recommendation is appropriate given the recipient's particular investment needs, objectives and financial circumstances. We recommend that investors independently evaluate particular investments and strategies, and encourage investors to seek the advice of a financial advisor. Oppenheimer & Co. Inc. will not treat non-client recipients as its clients solely by virtue of their receiving this report. Past performance is not a guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance of any security mentioned in this report. The price of the securities mentioned in this report and the income they produce may fluctuate and/or be adversely affected by exchange rates, and investors may realize losses on investments in such securities, including the loss of investment principal. Oppenheimer & Co. Inc. accepts no liability for any loss arising from the use of information contained in this report, except to the extent that liability may arise under specific statutes or regulations applicable to Oppenheimer & Co. Inc. All information, opinions and statistical data contained in this report were obtained or derived from public sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such information, opinion or statistical data is accurate or complete (with the exception of information contained in the Important Disclosures section of this report provided by Oppenheimer & Co. Inc. or individual research analysts), and they should not be relied upon as such. All estimates, opinions and recommendations expressed herein constitute judgments as

of the date of this report and are subject to change without notice. Nothing in this report constitutes legal, accounting or tax advice. Since the levels and bases of taxation can change, any reference in this report to the impact of taxation should not be construed as offering tax advice on the tax consequences of investments. As with any investment having potential tax implications, clients should consult with their own independent tax adviser. This report may provide addresses of, or contain hyperlinks to, Internet web sites. Oppenheimer & Co. Inc. has not reviewed the linked Internet web site of any third party and takes no responsibility for the contents thereof. Each such address or hyperlink is provided solely for the recipient's convenience and information, and the content of linked third party web sites is not in any way incorporated into this document. Recipients who choose to access such third-party web sites or follow such hyperlinks do so at their own risk.

This research is distributed in the UK and elsewhere throughout Europe, as third party research by Oppenheimer Europe Ltd, which is authorized and regulated by the Financial Conduct Authority (FCA). This research is for information purposes only and is not to be construed as a solicitation or an offer to purchase or sell investments or related financial instruments. This research is for distribution only to persons who are eligible counterparties or professional clients and is exempt from the general restrictions in section 21 of the Financial Services and Markets Act 2000 on the communication of invitations or inducements to engage in investment activity on the grounds that it is being distributed in the UK only to persons of a kind described in Article 19(5) (Investment Professionals) and 49(2) High Net Worth companies, unincorporated associations etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended). It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. In particular, this material is not for distribution to, and should not be relied upon by, retail clients, as defined under the rules of the FCA. Neither the FCA's protection rules nor compensation scheme may be applied.

Distribution in Hong Kong: This report is prepared for professional investors and is being distributed in Hong Kong by Oppenheimer Investments Asia Limited (OIAL) to persons whose business involves the acquisition, disposal or holding of securities, whether as principal or agent. OIAL, an affiliate of Oppenheimer & Co. Inc., is regulated by the Securities and Futures Commission for the conduct of dealing in securities, advising on securities, and advising on Corporate Finance. For professional investors in Hong Kong, please contact researchasia@opco.com for all matters and queries relating to this report. This report or any portion hereof may not be reprinted, sold, or redistributed without the written consent of Oppenheimer & Co. Inc.

This report or any portion hereof may not be reprinted, sold, or redistributed without the written consent of Oppenheimer & Co. Inc. Copyright © Oppenheimer & Co. Inc. 2015.